<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637685</url>
  </required_header>
  <id_info>
    <org_study_id>288743</org_study_id>
    <nct_id>NCT04637685</nct_id>
  </id_info>
  <brief_title>The Effect of Infusion Pressure on the Outcomes of Phacoemulsification Surgery; the ENHANSE Study</brief_title>
  <acronym>ENHANSE</acronym>
  <official_title>The Enhanse Study The Effect of Infusion Pressure on the Outcomes of Phacoemulsification Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Tyneside and Sunderland NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Tyneside and Sunderland NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of infusion pressure on the outcomes of phacoemulsification surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Centurion phacoemulsification system with active sentry allows efficient cataract surgery&#xD;
      with safe use of high vacuums, whilst allowing low and physiological infusion pressures,&#xD;
      significantly lower than other surgical systems. There are reasons to expect that this will&#xD;
      lead to patient benefit but it is uncertain if low infusion pressure during&#xD;
      phacoemulsification will lead to improved outcomes. This is of particular interest in&#xD;
      patients with vascular retinopathies such as diabetic retinopathy where the retinal&#xD;
      vasculature is compromised, as well as glaucoma and other optic neuropathies where there is&#xD;
      established nerve fibre layer loss.&#xD;
&#xD;
      The investigator will carry out a feasibility study with a two surgeon RCT of 70 patients&#xD;
      with diabetic retinopathy and/or glaucoma undergoing phacoemulsification with randomisation&#xD;
      of two different infusion pressures (low (30mmHg) versus the higher pressure (~70mmHg) as&#xD;
      currently used) using the active sentry system with assessment of a range of exploratory&#xD;
      endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>All outcome assessors will be masked to treatment group allocation. The surgeon will not be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>From the start to the end of the 10 month planned recruitment period</time_frame>
    <description>The study has been designed as a feasibility study to assess recruitment rate. We will measure rate of recruitment to study (persons per month)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness on SD OCT</measure>
    <time_frame>Between baseline and day 40</time_frame>
    <description>The above will be measured preoperatively and compared with day 40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foveal avascular zone size on optical coherence tomography angiography between baseline and day 40</measure>
    <time_frame>Between baseline and day 40</time_frame>
    <description>The above will be measured preoperatively and compared with day 40</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Standard pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 70mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low or physiological pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 30mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Centurion Phacoemulsification System</intervention_name>
    <description>Infusion Pressure</description>
    <arm_group_label>Low or physiological pressure</arm_group_label>
    <arm_group_label>Standard pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with cataract undergoing routine phacoemulsification with either diabetic&#xD;
             retinopathy or glaucoma of any degree&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dense cataract precluding adequate retinal imaging&#xD;
&#xD;
          -  posterior polar cataract&#xD;
&#xD;
          -  subluxated cataract,&#xD;
&#xD;
          -  other vision affecting pathology,&#xD;
&#xD;
          -  severe glaucoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Steel</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Tyneside and Sunderland NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve Dodds</last_name>
    <phone>+441915699039</phone>
    <email>steven.dodds@chsft.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Steel</last_name>
    <phone>+441915656256</phone>
    <email>david.steel@chsft.nhs.uk</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

